Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

A $10.3 million grant from the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, will fund ...

SemiAnalysis debunks the $6 million DeepSeek AI training cost myth, revealing a massive $1.3 billion investment in ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

At longevity clinics, people are shelling out for exhaustive medical tests and treatments like plasma exchange and peptide ...

I intend to do that. "We can accept high health care costs as inevitable or take on the opaque system to lower costs and increase transparency for all Hoosier families," Braun said, adding ...

CRISPR Therapeutics AG (NASDAQ ... diluting existing shareholders. Moreover, the high costs associated with gene therapy production and the complex manufacturing process could further pressure ...